Zimmer Biomet (NYSE ZBH) is a medical devices company based out of Indiana, USA. The company has collaborated with Apple to provide a unique care management system. Recently, Zimmer announced some additional features related to gait measurement as part of the mymobility system of the Apple Watch.
Through the new features, vital data of knee and hip replacement patients will be communicated to their healthcare providers. The gait quality measurement metrics will also be added to Zimmer Biomet’s OrthoIntel Orthopedic Intelligence Platform. Gait analysis is a way to measure the way an individual walks. The method involves observing whether the individual can walk in a straight line.
Being able to provide the gait measurements to healthcare providers will aid the post-surgery care of the patient and identify any significant issues at the same time. It can potentially reduce the number of patient visits as well and enhance the overall patient experience.
The global joint replacement market is expected to grow at a CAGR of around 4.5% from 2020 to 2025. The primary drivers of the market will be the rising occurrences of orthopedic injury, an ageing population, and the increasing prevalence of osteoarthritis.
According to Bryan Hanson, CEO, Zimmer Biomet, “Digital transformation of care has been central to Zimmer Biomet’s ongoing evolution and growth prior to the COVID-19 pandemic and is even more important now.” He further added, “Through mymobility with Apple Watch, we are providing new and effective ways to optimize the patient experience and mitigate patient issues, without requiring additional in-office visits.”
In other ZBH news, the company’s Dental division has signed a deal with AcelRx Pharmaceuticals to distribute the latter’s opioid pain medicine Dsuvia to the US oral surgery and dental market. The exact financial details of the deal haven’t been disclosed.
ZBH stock closed at $134.24 on 27th June 2020, up 14.83% for the past month.